'Double whammy' for Roche as manufacturing patent losses loom


Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. Roche's so-called "Cabilly patents" protect a pivotal step in manufacturing therapeutic antibodies, but end on Dec. 18, 2018.



from Biotech News